Indication
Respiratory distress syndrome in the newborn
Respiratory distress syndrome in the newborn, historically termed hyaline membrane disease, is an acute pulmonary disorder that predominantly affects premature infants due to developmental insufficiency of pulmonary surfactant production and structural lung immaturity. Read more about Respiratory distress syndrome in the newborn
5 drugs 5 manufacturers
Drugs that treat it
Common Respiratory distress syndrome in the newborn therapies.
CUROSURF (poractant alfa)
INFASURF (calfactant)
SURFAXIN (lucinactant)
CUROSURF (poractant alfa)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonRespiratory distress syndrome in the newborn, historically termed hyaline membrane disease, is an acute pulmonary disorder that predominantly affects premature infants due to developmental insufficiency of pulmonary surfactant production and structural lung immaturity.
Deficient surfactant leads to increased alveolar surface tension, resulting in widespread microatelectasis, decreased lung compliance, ventilation-perfusion mismatch, and progressive hypoxemia.
Clinically, affected neonates present shortly after birth with marked signs of respiratory compromise, including tachypnea, intercostal and subcostal retractions, expiratory grunting, nasal flaring, and cyanosis.
Without prompt intervention, the condition can advance to respiratory failure and severe acidosis.
- nih.gov
Respiratory distress syndrome in the newborn, historically termed hyaline membrane disease, is an acute pulmonary disorder that predominantly affects premature infants due to developmental insufficiency of pulmonary surfactant production and structural lung immaturity Deficient surfactant leads to increased alveolar surface tension, resulting in widespread microatelectasis, decreased lung compliance, ventilation-perfusion mismatch, and progressive hypoxemia Without prompt intervention, the condi...
- childrenshospital.org
Respiratory distress syndrome in the newborn, historically termed hyaline membrane disease, is an acute pulmonary disorder that predominantly affects premature infants due to developmental insufficiency of pulmonary surfactant production and structural lung immaturity Clinically, affected neonates present shortly after birth with marked signs of respiratory compromise, including tachypnea, intercostal and subcostal retractions, expiratory grunting, nasal flaring, and cyanosis
- nih.gov
Clinically, affected neonates present shortly after birth with marked signs of respiratory compromise, including tachypnea, intercostal and subcostal retractions, expiratory grunting, nasal flaring, and cyanosis Without prompt intervention, the condition can advance to respiratory failure and severe acidosis
- nih.gov
Without prompt intervention, the condition can advance to respiratory failure and severe acidosis
Personalize your experience
Follow Respiratory distress syndrome in the newborn and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.